Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
29 July 2020 - 9:05PM
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the
“Company”), a clinical-stage dermatology company focused on
identifying, developing and commercializing branded and generic
topical drug products for the treatment of skin diseases, will
report second quarter 2020 financial results on Thursday, August 6,
2020 at 7:05 AM ET.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on
identifying, developing and commercializing branded and generic
topical drug products for the treatment of skin
diseases. Sol-Gel leverages its proprietary
microencapsulation technology platform for Twyneo, for the
treatment of acne vulgaris, and Epsolay, for the treatment of
papulopustular rosacea. The Company’s pipeline also includes
SGT-210, an early-stage topical epidermal growth factor receptor
inhibitor, erlotinib, for the treatment of palmoplantar
keratoderma, and preclinical assets tapinarof and roflumilast. For
additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:Gilad MamlokChief Financial
Officer+972-8-9313433
Investor Contact:Lee M. SternSolebury Trout
+1-646-378-2922lstern@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From Apr 2024 to May 2024
Sol Gel Technologies (NASDAQ:SLGL)
Historical Stock Chart
From May 2023 to May 2024